Scinai Immunotherapeutics
SCNI
9 hedge funds and large institutions have $534K invested in Scinai Immunotherapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 3 closing their positions.
73% more capital invested
Capital invested by funds: $309K → $534K (+$225K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
10% less funds holding
Funds holding: 10 → 9 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$465K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$69.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$654 |
| 4 |
Morgan Stanley
New York
|
+$128 |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$64 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$15.7K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14.9K |
| 3 |
Credit Agricole
Montrouge Cedex,
France
|
-$598 |
| 4 |
NC
NewSquare Capital
Newtown Square,
Pennsylvania
|
-$3 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $315K | +$465K | +36,245 | New |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $213K | +$69.3K | +5,404 | +28% |
|
|
3
RhumbLine Advisers
Boston,
Massachusetts
| $3.08K | +$64 | +5 | +1% |
|
|
4
Morgan Stanley
New York
| $1.99K | +$128 | +10 | +5% |
|
|
5
UBS Group
Zurich,
Switzerland
| $717 | +$654 | +51 | +165% |
|
|
APC
6
Aspire Private Capital
Cornelius,
North Carolina
| $139 | – | – | – |
|
|
GRP
7
Global Retirement Partners
San Rafael,
California
| $38 | – | – | – |
|
8
Wells Fargo
San Francisco,
California
| $17 | – | – | – |
|
9
Qube Research & Technologies (QRT)
London,
United Kingdom
| $6 | +$13 | +1 | New |
|
|
10
Millennium Management
New York
| – | -$15.7K | -1,158 | Closed |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$14.9K | -1,092 | Closed |
|
|
12
Credit Agricole
Montrouge Cedex,
France
| – | -$598 | -42 | Closed |
|
|
NC
13
NewSquare Capital
Newtown Square,
Pennsylvania
| – | -$3 | – | – |
|
SCNI Hedge Fund Activity: Q3 2023 in Review
9 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2023, worth a combined $534K — up 73% from $309K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SCNI and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 4 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $465K. The largest seller was Millennium Management, exiting entirely with an estimated $15.7K sold.
- 9 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2023, down from 10 in Q2 2023.
- Funds reported $534K of Scinai Immunotherapeutics stock for Q3 2023, up 73% quarter-over-quarter.
- 2 funds opened new Scinai Immunotherapeutics positions in Q3 2023 and 3 closed out, a net change of -1 holder.
- The largest Scinai Immunotherapeutics buyer in Q3 2023 was Armistice Capital, an estimated $465K added.
- The largest Scinai Immunotherapeutics seller in Q3 2023 was Millennium Management, an estimated $15.7K sold.
Based on aggregated 13F filings for Q3 2023.